Thomas Brutnell serves as the vice president of Gateway Biotechnology, a St. Louis, Missouri-based startup focused on preventing noise-induced hearing loss.
In 2020, Gateway Biotechnology secured two-year federal grant funding of $2.2 million through the Phase II Small Business Innovation (SBIR) program with the National Institute of Health. Gateway is utilizing the funding to advance its research and development of a plant natural product for the treatment of tinnitus, which involves ringing in the ears and is typically associated with hearing loss.
Currently, no tinnitus treatments are FDA approved, yet nearly 20 million Americans suffer from some form of tinnitus. The grant will help Gateway to continue working on pilot studies and advance progress toward clinical trials. Since its founding in 2011, Gateway has been supported by BioGenerator, the investment arm of BioSTL, and various SBIR and Small Business Technology Transfer Grants. The firm has also received recently secured funding through a contract with the United States Army for a phase II clinical trial that will be conducted in collaboration with scientists at Washington University in St. Louis and the University of Akron to test the efficacy of a drug in the treatment and prevention of noise-induced hearing loss.
In 2020, Gateway Biotechnology secured two-year federal grant funding of $2.2 million through the Phase II Small Business Innovation (SBIR) program with the National Institute of Health. Gateway is utilizing the funding to advance its research and development of a plant natural product for the treatment of tinnitus, which involves ringing in the ears and is typically associated with hearing loss.
Currently, no tinnitus treatments are FDA approved, yet nearly 20 million Americans suffer from some form of tinnitus. The grant will help Gateway to continue working on pilot studies and advance progress toward clinical trials. Since its founding in 2011, Gateway has been supported by BioGenerator, the investment arm of BioSTL, and various SBIR and Small Business Technology Transfer Grants. The firm has also received recently secured funding through a contract with the United States Army for a phase II clinical trial that will be conducted in collaboration with scientists at Washington University in St. Louis and the University of Akron to test the efficacy of a drug in the treatment and prevention of noise-induced hearing loss.
